Customer-focused R&D and industry-academia-government collaboration
First written in FY2016. 31 of 37 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Increase in annual R&D expensesAnnual report
「R&D expenses for the consolidated fiscal year were ¥79 million.」
The company continued R&D based on interaction with customers, collection of information from Japan and abroad, and testing and analysis at farms and other facilities. R&D expenses increased from ¥74 million in the previous fiscal year to ¥79 million. - FY2026-H1Higher interim-period R&D expensesAnnual report
「Total R&D expenses for the current consolidated interim period were ¥40 million.」
The company continued its R&D activities, and R&D expenses increased from ¥36 million in the same period of the previous year to ¥40 million. - FY2025RestatedAnnual report
「The company's R&D structure involves deepening interaction with customers at 5 plants nationwide through close information exchange, study sessions and technical guidance, and collecting and reviewing the latest information from Japan and abroad.」
The company continues its R&D structure leveraging 5 plants nationwide, interaction with customers, and testing and analysis at company-operated farms. R&D expenses were ¥74 million. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the current interim consolidated period were ¥36 million.」
The company continues its R&D activities and recorded ¥36 million in R&D expenses for the cumulative interim period of the consolidated fiscal year. - FY2024RestatedAnnual report
「The company's R&D structure involves deepening interaction with customers at 5 plants nationwide through close information exchange, study sessions and technical guidance, and collecting and reviewing the latest information from Japan and abroad.」
The company continued its R&D structure leveraging 5 plants nationwide, interaction with customers, and testing and analysis at company-operated farms and other facilities. R&D expenses for the consolidated fiscal year were ¥71 million. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the consolidated cumulative period of the third quarter under review were ¥56 million.」
The company continues its R&D activities and recorded ¥56 million in R&D expenses for the cumulative third quarter of the consolidated fiscal year. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the current second-quarter cumulative consolidated period were ¥35 million.」
The company continues its R&D activities and recorded ¥35 million in R&D expenses for the cumulative second quarter of the consolidated fiscal year. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥14 million.」
The company continues its R&D activities and recorded ¥14 million in R&D expenses for the cumulative first quarter of the consolidated fiscal year. - FY2023AdvancedAnnual report
「The company's R&D structure involves deepening interaction with customers at 5 plants nationwide through close information exchange, study sessions and technical guidance, conducting research and development in response to customer needs, and consolidating information at the central research laboratory for sharing throughout the company.」
The company continued its customer-focused R&D structure and conducted specific R&D for poultry, swine and cattle. R&D expenses were ¥74 million. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the consolidated fiscal year were ¥59 million.」
The company continues its R&D activities and recorded ¥59 million in R&D expenses for the cumulative third quarter of the consolidated fiscal year. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the consolidated fiscal year were ¥39 million.」
The company continues its R&D activities and recorded ¥39 million in R&D expenses for the cumulative second quarter of the consolidated fiscal year. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the current consolidated cumulative period were ¥16 million.」
The company continues its R&D activities and recorded ¥16 million in R&D expenses for the cumulative first quarter of the consolidated fiscal year. - FY2022AdvancedAnnual report
「During the fiscal year, the company conducted feed research and development with the aim of improving product quality and livestock production performance. The results of research during the consolidated fiscal year are as follows. In the poultry business, the company developed and sold feed that maintained quality while reducing the use of fats and oils in feed ingredients, whose prices have continued to rise in recent years, by using digestive enzymes. In addition, it developed and sold feed using new food-residue resources and is pursuing sustainable development. The company also developed feed using herb extracts with antibacterial properties, which is expected to promote chicken health and increase output. In the swine business, the company is researching the formulation balance of digestive enzymes and ingredients used in feed to improve feed performance, with the aim of improving production performance and meat quality.」
The company continued its customer-focused R&D structure and industry-academia-government collaboration, making progress in specific development, sales and research activities, including feed using digestive enzymes, feed using food-residue resources, feed using herb extracts, and research into digestive enzymes and formulation balance for swine. R&D expenses were ¥83 million. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated fiscal year were ¥67 million.」
The company continues its R&D activities, with R&D expenses for the cumulative third quarter of the consolidated fiscal year totaling ¥67 million. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the current consolidated cumulative period were ¥41 million.」
The company continues its R&D activities and recorded ¥41 million in R&D expenses for the cumulative second quarter of the consolidated fiscal year. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥17 million.」
The company continues its R&D activities and recorded ¥17 million in R&D expenses for the cumulative first quarter of the consolidated fiscal year. - FY2021AdvancedAnnual report
「During the fiscal year, the company conducted feed research and development with the aim of improving product quality and livestock production performance. In the poultry business, it investigated the intestinal bacteria of chickens and developed and sold feed designed to improve immunity by combining multiple probiotics that increase beneficial bacteria.」
The company continued its customer-focused R&D structure and developed and sold feed designed to improve immunity by combining multiple probiotics, as well as feed using mineral-based ingredients to address loose stools and unpleasant odors. R&D expenses were ¥85 million. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the consolidated fiscal year were ¥68 million.」
The company continues its R&D activities, with R&D expenses for the cumulative third quarter of the consolidated fiscal year totaling ¥68 million. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the consolidated cumulative period of the second quarter under review were ¥43 million.」
The company continues its R&D activities, with R&D expenses for the cumulative second quarter of the consolidated fiscal year totaling ¥43 million. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the cumulative period of the first quarter were ¥18 million.」
The company continues its R&D activities and recorded ¥18 million in R&D expenses for the cumulative first quarter of the consolidated fiscal year. - FY2020RestatedAnnual report
「Our R&D structure involves deepening engagement at 5 plants nationwide through close information exchange, study sessions and technical guidance with customers, conducting research and development based on customer needs, and consolidating and sharing the information company-wide at the Central Research Institute in Kobe.」
The company continues to maintain an R&D structure leveraging 5 plants nationwide, a central research laboratory, company-operated farms, universities and public institutions, and other resources. R&D expenses for the consolidated fiscal year were ¥90 million. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the consolidated fiscal year were ¥72 million.」
The company continues its R&D activities and recorded ¥72 million in R&D expenses for the cumulative third quarter of the consolidated fiscal year. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the cumulative period of the second quarter were ¥46 million.」
The company continues its R&D activities, with R&D expenses for the cumulative second quarter of the consolidated fiscal year totaling ¥46 million. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥19 million.」
The company continues its R&D activities and recorded ¥19 million in R&D expenses for the cumulative first quarter of the consolidated fiscal year. - FY2019RestatedAnnual report
「Our R&D structure involves deepening engagement at 5 plants nationwide through close information exchange, study sessions and technical guidance with customers, conducting research and development based on customer needs, and consolidating and sharing the information company-wide at the Central Research Institute in Kobe.」
The company continues to maintain a customer-focused R&D structure leveraging 5 plants nationwide, a central research laboratory, company-operated farms, and universities and public institutions. R&D expenses for the consolidated fiscal year were ¥92 million. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the consolidated cumulative period of the third quarter under review were ¥73 million.」
R&D activities continued, and R&D expenses for the cumulative period of the third quarter were ¥73 million. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the cumulative period of the second quarter were ¥46 million.」
R&D activities continued, and R&D expenses for the cumulative period of the second quarter were ¥46 million. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the cumulative period of the first quarter were ¥18 million.」
R&D activities continued, and ¥18 million in R&D expenses was recorded for the cumulative period of the first quarter. - FY2018RestatedAnnual report
「Our R&D structure involves deepening engagement at 5 plants nationwide through close information exchange, study sessions and technical guidance with customers, conducting research and development based on customer needs, and consolidating the information at the Central Research Institute in Kobe.」
The Company continues its customer-focused R&D structure using 5 plants, the Central Research Institute, directly operated farms, universities and public institutions. R&D expenses were ¥96 million. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the cumulative period of the third quarter were ¥77 million.」
R&D activities continued, and R&D expenses for the cumulative period of the third quarter were ¥77 million. - FY2018-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated fiscal year were ¥47 million.」
R&D activities continued, and R&D expenses for the cumulative period of the second quarter were ¥47 million. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the cumulative period of the first quarter were ¥18 million.」
R&D activities continued, and ¥18 million in R&D expenses was recorded for the cumulative period of the first quarter. - FY2017RestatedAnnual report
「Our R&D structure involves deepening engagement at 5 plants nationwide through close information exchange, study sessions and technical guidance with customers, conducting research and development based on customer needs, and consolidating the information at the Central Research Institute in Kobe.」
The Company continued its R&D structure using 5 plants, the Central Research Institute, directly operated farms, universities and public institutions, and R&D expenses for the fiscal year were ¥98 million. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the cumulative period of the third quarter were ¥79 million.」
R&D activities continued, and R&D expenses for the cumulative period of the third quarter were ¥79 million. - FY2017-Q2RestatedAnnual report
「Total R&D expenses for the cumulative period of the second quarter were ¥49 million.」
R&D activities continued, and R&D expenses for the cumulative period of the second quarter were ¥49 million. - FY2017-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥19 million.」
R&D activities continued, and ¥19 million in R&D expenses was recorded for the quarter. - FY2016First statedAnnual report
「Our R&D structure involves deepening engagement at 5 plants nationwide through close information exchange, study sessions and technical guidance with customers, conducting research and development based on customer needs, and consolidating the information at the Central Research Institute in Kobe.」
The Company uses 5 plants, the Central Research Institute, directly operated farms, universities and public institutions, and recorded R&D expenses of ¥96 million for the fiscal year.